Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > NASH partnership

<< Previous

Bullboard Posts

Next >>

Comment by FredTheVoiceon Mar 09, 2021 11:24am

82 Views

Post# 32752527

RE:RE:RE:NASH partnership

Analia, we all need spring fast and sweet, still want you in my foursome......

Yes, I care about bad moves and impact on sharholders, I am one of them,

But still think that TH did the right move, giving some visibility with that bought deal. Sounds strange, but Th was out of the radar, now more visible, and cash in place to start both protocols.

Maybe not an "hole in one" before summer, but....

Cheers,

FTV.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?